N/A N=79 Functional Rehabilitation of Older Patients With Schizophrenia
Psychotic Disorders · Schizoaffective Disorder · Schizophrenia
Primary: Independent Living Skills Survey (ILSS) — 0.66; 0.70; 0.68; 0.71 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease
Sensorineural Hearing Loss · Autoimmune Inner Ear Disease
Primary: To Assess the Potential Efficacy of Anakinra in Improving Hearing Thresholds in Corticosteroid-resistant Patients With Autoimmune Inner Ear Disease — 7 responders
N/A N=90 Exercise Training and Glucose Metabolism in Aging
Type 2 Diabetes Mellitus · Impaired Glucose Tolerance (Prediabetes)
Primary: Baseline Glucose Utilization — 0.0062; 0.0035 µmol/kgFFM/pmol insulin/min
Phase 3 N=416 Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children
Healthy
Primary: Percentage of Participants With Healthy Children Aged From 6 Months to <18 Years With Seroconversion — 62.02; 76.81; 53.41; 57.35 percentage of paticipants
N/A N=43 Letrozole as a Treatment of Endometrial Cancer
Endometrial Carcinoma
Primary: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer — -3.75; 1.583 percentage of Ki67 staining cells — p=0.0373
Phase 3 N=656 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
Advanced Gastric Cancer
Primary: Overall Survival (OS) — 5.39; 4.34 Months
Phase 2 N=83 Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer
Prostate Cancer
Primary: PSA Slope (Trajectory) or the Change in PSA Level Over Time — 0.59; 0.27 ng/mL
Phase 2 N=30 Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Polycystic Kidney Diseases
Primary: Change in GFR From Baseline to 12 Months — 72.8; 70.3; 73.1; 74.4 ml/min/1.73m^2 — p=<0.01
Phase 2 N=55 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Malignant Salivary Gland Neoplasm · Recurrent Salivary Gland Carcinoma · Salivary Gland Adenoid Cystic Carcinoma
Primary: Response Rate — 0; 0; 1; 0 participants
Phase 2 N=265 A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Colorectal Cancer
Primary: Investigator-assessed Progression-Free Survival (PFS) — 9.4; 10.7 months — p=0.706
Phase 2 N=12 Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)
Lymphoma, Non-Hodgkin
Primary: Optimal Bendamustine Dosage for Further Studies — 60 mg/m^2
Phase 3 N=40 Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
Retinal Vein Occlusion
Primary: Number of Participants Who Had a >30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex — 7; 5; 7; 4 participants
Phase 4 N=200 Iota-Carrageenan Nasal Spray in Common Cold
Common Cold
Primary: Total Symptom Score (TSS) Over Days 2 to 4 (TSS2-4) — 6.390; 5.777 units on a scale — p=0.0895
Phase 2 N=72 Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma · Neoplasm Metastases
Primary: To Determine the Overall Response Rate of Combination Therapy With Gemcitabine and Sunitinib in Sarcomatoid and/or Poor-risk mRCC Patients as First Line Therapy. — 25…
Phase 4 N=65 Effect of Aged Garlic Extract on Atherosclerosis
Metabolic Syndrome
Primary: CT Angiography Plaque — 0.17; -1.53 percent change of low attenuation plaque